Table 1.

Selected studies evaluating the safety and utility of high-dose daptomycin

Authors	Type of Study	Patient Population	Number of Patients	Daptomycin Therapy	Results and Major Conclusions	Reference
Moise PA, et al. 2009	Retrospective, observational	Subset of patients 18 years or older from the Cubicin Outcomes Registry and Experience (CORE) database with any site of infection	Total = 94 IE = 15	Median daily dose of 8 mg/kg for 15 days (1 – 90 days)	Clinically evaluable subset of 74 patients. Clinical cure or improvement in 89% of all patients. Clinical cure or improvement in IE of 69%. Two patients discontinued daptomycin secondary to adverse events	51
Kullar R, et al. 2011	Retrospective, observational	Patients 18 years or older with confirmed or suspected Gram-positive infections (S. aureus or enterococci) at any site	Total = 250 IE = 31	Median daily dose of daptomycin was 8.9 mg/kg (IQR 8.0 – 10.0 mg/kg) for 10 – 13 days (IQR 5 – 18 days) depending on organism	Clinically evaluable subset of 227 patients. Clinical cure or improvement in 83.6%. Clinical failure in 5 IE patients	52
Carugati, et al. 2013	Prospective, cohort	Subset of patients 16 years or older from the International Collaboration on Endocarditis Daptomycin Study (ICE-DS) database with left-sided endocarditis	Total (IE) = 178 Daptomycin treated = 29	Median daily dose of 9.2 mg/kg (range, 7.7 to 10.0 mg/kg) for 39 days (range, 25.0 to 43.0 days)	Time to clearance of bacteremia was significantly faster with daptomycin (1 versus 5 days). Higher dose daptomycin was not associated with an increase in adverse events	28
Durante-Mangoni, et al. 2012	Case series	Patients with staphylococcal infective endocarditis on a cardiac implantable electronic device	Total = 25	Median daily dose of 8.3 mg/kg (6.4 – 10.7) for 20 days (8 – 52)	All patients were clinically evaluable. Clinical success of 80%. No serious adverse events related to high-dose daptomycin	54
Murray KP, et al. 2013	Matched retrospective, cohort	Patients with MRSA bacteremia on vancomycin or daptomycin matched according to age, Pitt bacteremia score, and source of bacteremia	Total = 170 Daptomycin IE = 20	Median daily dose of 8.4 mg/kg (IQR 6.3 – 9.9 mg/kg)	Clinical failure at 30 days was significantly lower in the daptomycin-treated patients. Daptomycin treatment was associated with reduced mortality compared to vancomycin (3.5% vs. 12.9%, p=0.047).	16
Kullar R, et al. 2013	Retrospective, observational	Patients with definitive or possible RS and/or LS IE	Total = 70 RS IE = 33 LS IE = 35 LS/RS = 2	Median daily dose of daptomycin was 9.8 mg/kg (IQR 8.2 – 10.0 mg/kg) for	Clinically evaluable subset of 64 patients. Clinical success in 85.9% of patients. Two patients experienced adverse events secondary to daptomycin	55

*IE = infective endocarditis, IRQ = Interquartile range, RS = right-sided, LS = left-sided